HA
HAE
HAEMONETICS CORP
$78.20
-2.05%
$3.6B
No data for this timeframe.
Vol
Market Cap$3.6B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (73%)
Inst. Holders50 funds
Inst. Value$1.7B
Inst. Activity18 buys / 14 sells
SEC Reports4
Exchange NYSE·Sector Surgical & Medical Instruments & Apparatus·Inc. MA·CIK 0000313143·Prev Close $79.84
Recent Activity
Jun 9, 2026
SEC
Haemonetics Corp filed definitive additional proxy soliciting materials (DEFA14A) on June 9, 2026, filed by management.
DEFA14A — Impact 5/10
Jun 9, 2026
short_volume
Short Volume: HAE — 59.1% short (0.6M / 1.1M)
Short: 625,874 | Exempt: 33,791 | TRF Vol: 1,059,374 | Short Ratio: 59.1% | Off-exchange volume (dar
Jun 5, 2026
SEC
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood Center segments into
8-K — Impact 2/10
Jun 5, 2026
Insider
Miller Laurie A. surrendered for taxes 313 shares
SVP, Human Resources @ $71.28 ($22.3K)
Jun 5, 2026
Insider
Maunsell Farris Maryanne surrendered for taxes 259 shares
VP, Chief Accounting Officer @ $71.28 ($18.5K)
May 15, 2026
Insider
Simon, Christopher surrendered for taxes 9,681 shares
President & CEO @ $56.29 ($544.9K)
May 7, 2026
SEC
Haemonetics Q4 FY2026 revenue grew 4.8% YoY to $346.4M, beating estimates, while adjusted EPS of $1.29 edged past consen
8-K — Impact 4/10
Inst.
LONDON CO OF VIRGINIA — ADD
352,807 shares ($19.9M)
Price Targets
$83.10
+6.3% upside
Buy
Current $78.20
Low $62.00
Median $84.50
High $104.00
10 analysts
$62.00
$104.00
Analyst Ratings
5Strong Buy
6Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| May 22, 2026 | B of A Securities | UPGRADE | Neutral → Buy |
| May 12, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | JP Morgan | MAINTAIN | Neutral → Neutral |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.09 ▼ -1.4% | $1.03 — $1.14 | -1% YoY | 11 |
| Next Q | $1.28 | $1.19 — $1.34 | 1% YoY | 11 |
| Current FY | $5.22 | $5.17 — $5.26 | 5% YoY | 11 |
| Next FY | $5.76 | $5.51 — $6.11 | 10% YoY | 11 |
Latest Reports
NEUTRAL
DEFA14A
5/10
Haemonetics Corp filed definitive additional proxy soliciting materials (DEFA14A) on June 9, 2026, filed by management.
Jun 9, 2026
NEUTRAL
8-K
2/10
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood Center segments into
Jun 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $316.7M | — |
| Neuberger Berman Group LLC | $200.6M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $144.2M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $117.8M | — |
| STATE STREET CORP | $99.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Miller Laurie | F | $22.3K |
| Jun 5, 2026 | Maunsell Farris | F | $18.5K |
| May 15, 2026 | Simon, Christopher | F | $544.9K |
| May 15, 2026 | Simon, Christopher | A | $0.00 |
| May 15, 2026 | Miller Laurie | F | $53.4K |
50 institutional holders with $1.7B total value (30,920,256 shares) as of 2026-Q1. Top holders: BlackRock,, Neuberger, VANGUARD. Net buying activity: 18 institutions added/increased vs 14 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5,619,979 | $316.7M | 18.2% | — |
| 2 | Neuberger Berman Group LLC | 3,560,918 | $200.6M | 11.5% | — |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,559,316 | $144.2M | 8.3% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,090,389 | $117.8M | 6.8% | — |
| 5 | STATE STREET CORP | 1,772,898 | $99.9M | 5.7% | — |
| 6 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,383,004 | $77.9M | 4.5% | DOUBLED +994.7% |
| 7 | DIMENSIONAL FUND ADVISORS LP | 1,326,057 | $74.7M | 4.3% | — |
| 8 | FMR LLC | 1,275,886 | $71.9M | 4.1% | — |
| 9 | GOLDMAN SACHS GROUP INC | 952,820 | $53.7M | 3.1% | — |
| 10 | Allspring Global Investments Holdings, LLC | 890,224 | $50.1M | 2.9% | — |
| 11 | ROYAL BANK OF CANADA | 857,965 | $48.4M | 2.8% | — |
| 12 | FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 841,017 | $47.4M | 2.7% | — |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 572,100 | $32.2M | 1.8% | — |
| 14 | BANK OF AMERICA CORP /DE/ | 512,183 | $28.9M | 1.7% | ADD +44.2% |
| 15 | Boston Trust Walden Corp | 501,885 | $28.3M | 1.6% | TRIM -39.3% |
| 16 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 491,747 | $27.7M | 1.6% | — |
| 17 | FRANKLIN RESOURCES INC | 400,917 | $22.6M | 1.3% | TRIM -26.0% |
| 18 | DEUTSCHE BANK AG\ | 358,882 | $20.2M | 1.2% | ADD +38.8% |
| 19 | LONDON CO OF VIRGINIA | 352,807 | $19.9M | 1.1% | ADD +33.9% |
| 20 | VANGUARD FIDUCIARY TRUST CO | 323,585 | $18.2M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| LONDON CO OF VIRGINIA | ADD | 263,565 | 352,807 | +33.9% | $19.9M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 432,955 | 320,010 | -26.1% | $18.0M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 562,949 | 293,439 | -47.9% | $16.5M | 2026-Q1 |
| Trexquant Investment LP | ADD | 125,524 | 218,010 | +73.7% | $12.3M | 2026-Q1 |
| Assenagon Asset Management S.A. | DOUBLED | 76,491 | 177,401 | +131.9% | $10.0M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 46,142 | 77,222 | +67.4% | $4.4M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 853,379 | 56,868 | -93.3% | $3.2M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 404 | 50,804 | +12475.2% | $2.9M | 2026-Q1 |
| Gotham Asset Management, LLC | DOUBLED | 18,814 | 48,842 | +159.6% | $2.8M | 2026-Q1 |
| ExodusPoint Capital Management, LP | TRIM | 96,318 | 47,750 | -50.4% | $2.7M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 25,534 | 39,326 | +54.0% | $2.2M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 65,516 | 38,474 | -41.3% | $2.2M | 2026-Q1 |
| HSBC HOLDINGS PLC | DOUBLED | 10,972 | 37,256 | +239.6% | $2.1M | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 61,621 | 29,077 | -52.8% | $1.6M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 14,471 | 27,493 | +90.0% | $1.5M | 2026-Q1 |
| JENNISON ASSOCIATES LLC | ADD | 12,103 | 22,536 | +86.2% | $1.3M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | DOUBLED | 6,300 | 17,400 | +176.2% | $980.7K | 2026-Q1 |
| Mariner, LLC | ADD | 11,091 | 14,851 | +33.9% | $836.5K | 2026-Q1 |
| EXCHANGE TRADED CONCEPTS, LLC | DOUBLED | 1,442 | 13,962 | +868.2% | $786.9K | 2026-Q1 |
| STIFEL FINANCIAL CORP | ADD | 6,951 | 9,008 | +29.6% | $507.7K | 2026-Q1 |
| BANK OF MONTREAL /CAN/ | DOUBLED | 4,077 | 8,617 | +111.4% | $485.7K | 2026-Q1 |
| Amundi | DOUBLED | 2,766 | 5,843 | +111.2% | $329.3K | 2026-Q1 |
| M&T BANK CORP | TRIM | 14,370 | 4,526 | -68.5% | $255.1K | 2026-Q1 |
| Holocene Advisors, LP | NEAR_EXIT | 1,264,271 | 4,522 | -99.6% | $254.9K | 2026-Q1 |
| LAZARD ASSET MANAGEMENT LLC | NEAR_EXIT | 3,659 | 707 | -80.7% | $39.8K | 2026-Q1 |
7 unique insiders with 17 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Miller Laurie A. | SVP, Human Resources | TAX W/H | 313 | $71.28 | $22.3K |
| Jun 5, 2026 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | TAX W/H | 259 | $71.28 | $18.5K |
| May 15, 2026 | Simon, Christopher | President & CEO | TAX W/H | 9,681 | $56.29 | $544.9K |
| May 15, 2026 | Simon, Christopher | President & CEO | AWARD | 78,344 | — | — |
| May 15, 2026 | Miller Laurie A. | SVP, Human Resources | TAX W/H | 948 | $56.29 | $53.4K |
| May 15, 2026 | Miller Laurie A. | SVP, Human Resources | AWARD | 13,323 | — | — |
| May 15, 2026 | Galvin Roy | EVP, Chief Commercial Officer | AWARD | 27,535 | — | — |
| May 15, 2026 | Galvin Roy | EVP, Chief Commercial Officer | TAX W/H | 879 | $56.29 | $49.5K |
| May 15, 2026 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | TAX W/H | 197 | $56.29 | $11.1K |
| May 15, 2026 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | AWARD | 2,220 | — | — |
| May 15, 2026 | DArecca James | EVP, Chief Financial Officer | TAX W/H | 2,505 | $56.29 | $141.0K |
| May 15, 2026 | DArecca James | EVP, Chief Financial Officer | AWARD | 29,312 | — | — |
| May 15, 2026 | Chan Frank | EVP, Chief Operating Officer | TAX W/H | 546 | $56.29 | $30.7K |
| May 15, 2026 | Chan Frank | EVP, Chief Operating Officer | AWARD | 27,535 | — | — |
| May 15, 2026 | Basil Michelle L | EVP and General Counsel | TAX W/H | 2,913 | $56.29 | $164.0K |
| May 15, 2026 | Basil Michelle L | EVP and General Counsel | AWARD | 28,424 | — | — |
| May 1, 2026 | DArecca James | EVP, Chief Financial Officer | TAX W/H | 655 | $59.26 | $38.8K |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.3/10.
NEUTRAL
DEFA14A
5/10
Haemonetics Corp filed definitive additional proxy soliciting materials (DEFA14A) on June 9, 2026, f
Jun 9, 2026
NEUTRAL
8-K
2/10
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood C
Jun 5, 2026
NEUTRAL
8-K
4/10
Haemonetics Q4 FY2026 revenue grew 4.8% YoY to $346.4M, beating estimates, while adjusted EPS of $1.
May 7, 2026
NEUTRAL
8-K
2/10
Director Charles J. Dockendorff will not stand for re-election at Haemonetics' 2026 annual meeting,
May 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (73% buy). Based on 15 analysts: 5 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$83.10 mean target
+6.3% upside
Buy (1.91)
$62.00 Low
$104.00 High
| Metric | Value |
|---|---|
| Current Price | $78.20 |
| Target Low | $62.00 |
| Target Mean | $83.10 |
| Target Median | $84.50 |
| Target High | $104.00 |
| # Analysts | 10 |
| Recommendation | Buy (1.91) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.09 | $1.03 | $1.14 | -1.2% | -1.4% | 2↑ 7↓ | $0.3B | 2.3% | 11 |
| Next Q 2026-09-30 |
$1.28 | $1.19 | $1.34 | 0.5% | +0.0% | 1↑ 7↓ | $0.3B | 4.7% | 11 |
| Current FY 2027-03-31 |
$5.22 | $5.17 | $5.26 | 5.2% | -0.0% | 2↑ 8↓ | $1.4B | 5.0% | 11 |
| Next FY 2028-03-31 |
$5.76 | $5.51 | $6.11 | 10.3% | -0.1% | 2↑ 5↓ | $1.5B | 5.3% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.087 | |
| 7d ago | $1.102 | -0.015 |
| 30d ago | $1.102 | -0.015 |
| 60d ago | $1.164 | -0.078 |
| 90d ago | $1.167 | -0.080 |
8 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| May 22, 2026 | B of A Securities | UPGRADE | Neutral | Buy |
| May 12, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Apr 7, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Mar 11, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 6, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 6, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 6, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Feb 6, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 2, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Jan 12, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Jan 9, 2026 | BTIG | REITERATE | Buy | Buy |
| Dec 17, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Baird | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Needham | DOWNGRADE | Buy | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 4 | 0 | 0 | 73% | |
| May 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Apr 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Mar 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Feb 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Jan 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: HAE — 59.1% short (0.6M / 1.1M)
Short: 625,874 | Exempt: 33,791 | TRF Vol: 1,059,374 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: HAE — 81.5% short (0.5M / 0.6M)
Short: 478,124 | Exempt: 1,697 | TRF Vol: 586,813 | Short Ratio: 81.5% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: HAE — 71.6% short (0.4M / 0.5M)
Short: 362,652 | Exempt: 0 | TRF Vol: 506,723 | Short Ratio: 71.6% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: HAE — 69.4% short (0.4M / 0.5M)
Short: 367,297 | Exempt: 4,400 | TRF Vol: 529,515 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: HAE — 57.6% short (0.3M / 0.6M)
Short: 345,121 | Exempt: 0 | TRF Vol: 599,684 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: HAE — 73,355 shares ($4.0M) failed to deliver
Settlement: 20260513, Price: $54.01, FTD Value: $3,961,903.55, HAEMONETICS CORP
May 7, 2026
earnings_calendar
HAE Q4 2026 Earnings After Market Close — 2026-05-07
May 6, 2026
short_volume
Short Volume: HAE — 61.6% short (0.3M / 0.5M)
Short: 320,331 | Exempt: 0 | TRF Vol: 519,741 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)